Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration
NCT ID: NCT00710229
Last Updated: 2010-06-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
320 participants
INTERVENTIONAL
2008-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration
NCT02257632
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
NCT00593450
Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab
NCT00559715
Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration
NCT01014468
Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab or Ranibizumab
NCT00605943
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Intravitreal injectin of Ranibizumab (3 monthly injection followed by monthly injectins as long as required
Ranibizumab
intravitreal injection
B
Intravitreal injectin of Bevacizumab (3 monthly injection followed by monthly injectins as long as required
Bevacizumab
intravitreal injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ranibizumab
intravitreal injection
Bevacizumab
intravitreal injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Active primary or recurrent subfoveal lesion with CNV secondary to AMD
Exclusion Criteria
* Prior treatment with verteporfin photodynamic therapy in the study eye
* Prior treatment with systemic bevacizumab
* Prior treatment with any intravitreal durg or verteprofin photodynamic therapy in the nonstudy eye within the 3 moths before the study entry
* Laser photocoagulation within 1 month before study entry in the study eye
* Previous participation in any clinical trial within 1 month before the entry of the study
* Subfoveal fibrosis or atrophy in the study eye
* CNV in either of the two eye due to causes other than AMD such as histoplasmosis or pathologica myopia
* Retinal pigment epithelial tear involving the macula in the study eye
* Any concurrent intraocular condition in the study eye that could either require medical or surgical intervention during the 12 month study period or that could contribute to a loss of best corrected visual acuity over the 12 months study period (e.g. diabetic retinopathy, cataract, uncontrolled glaucoma). The decision on exclusion is to be based on the opinion of the local principal investigator.
* Active intraocular inflammation
* Vitreous hemorrhage in the study eye
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Krankenanstalt Rudolfstiftung
UNKNOWN
Medical University of Vienna
OTHER
Medical University of Graz
OTHER
Medical University Innsbruck
OTHER
Krankenhaus der Barmherzigen Brüder Linz
OTHER
Universitätsaugenklinik Salzburg
UNKNOWN
Hospital Hietzing
OTHER
Hanuschkrankenhaus
UNKNOWN
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery
Vienna, Vienna, Austria
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Krebs I, Schmetterer L, Boltz A, Told R, Vecsei-Marlovits V, Egger S, Schonherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013 Mar;97(3):266-71. doi: 10.1136/bjophthalmol-2012-302391. Epub 2013 Jan 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EK 07-192-1007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.